Skip to main content
SpringerLink
Log in

A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The purpose of this study was to estimate the costs and benefits of the use of recombinant human erythropoietin (epoetin) in the treatment of anaemia arising from chronic renal failure. A 5-nation study, using an identical research protocol, was carried out by groups in France, Germany, Italy, Spain and the UK to identify the costs of the use of epoetin, the resource savings generated by such treatment and the effects of this treatment on the quality of life of patients. The latter was measured using the Rosser matrix of disability-distress states.

The results show that the use of epoetin can produce a competitive cost per quality-adjusted life-year (QALY) only in patients with serious incapacity. Use of epoetin in patients who are not transfusion dependent would be an expensive way of gaining health benefits, which would be achieved at considerable opportunity cost.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alter JH, Purcell RH, Shih JW, Melpolder JC, Houghton M, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. New England Journal of Medicine 321: 1494–1500, 1989

    Article  PubMed  CAS  Google Scholar 

  • Brown AL, Tucker B, Baker LRI, Raine AEG. Seizures related to blood transfusion and erythropoietin treatment in patients undergoing dialysis. British Medical Journal 299: 1258–1259, 1989

    Article  PubMed  CAS  Google Scholar 

  • Casati S, Campise M, Crepaldi M, Lobo J, Graziani G, et al. Haemodialysis efficiency after long term treatment with recombinant human erythropoietin. Nephrology, Dialysis and Transplantation 4: 718–720, 1989

    CAS  Google Scholar 

  • Clumeck N, Taelman H, Hermans P, Piot P, Schoumacher M, et al. A cluster of HIV infection among heterosexual people without apparent risk factors. New England Journal of Medicine 321: 1460–1462, 1989

    Article  PubMed  CAS  Google Scholar 

  • Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, et al. Treatment of chronic hepatitis C with recombinant interferon α. New England Journal of Medicine 321: 1501–1506, 1989

    Article  PubMed  CAS  Google Scholar 

  • Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman N, Murray L, et al. Recombinant interferon and therapy for chronic hepatitis C. New England Journal of Medicine 321: 1506–1510, 1989

    Article  PubMed  Google Scholar 

  • European Dialysis and Transplant Association. Combined Report XVII 1986, 1987

  • Evans R, Rader B, Mannien D. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Annals of Internal Medicine 263(6): 825–830, 1990

    CAS  Google Scholar 

  • Gudex C, Kind P. The QALY toolkit. Discussion paper No 38, Centre for Health Economics, University of York, York, 1988

    Google Scholar 

  • Hunter M. Survivals boost the case for EPO. Hospital Doctor CII(41): 4, 1991

    Google Scholar 

  • Kind P, Rosser R, Williams A. Valuation of quality of life. In Jones-Lee MW (Ed.) The value of life and safety, pp. 159–170, Elsevier, Amsterdam, 1982

    Google Scholar 

  • Leese B, Hutton J, Maynard A. The costs and benefits of the use of erythropoietin in the treatment of anaemia arising from chronic renal failure; a European study. Occasional Paper, Centre for Health Economics, University of York, York, 1990

    Google Scholar 

  • Leitman SF, Klein HG, Melpolder JJ, Read EJ, Esteban JI, et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. New England Journal of Medicine 321: 917–924, 1989

    Article  PubMed  CAS  Google Scholar 

  • Maynard A. Developing the health care market. Economic Journal 101: 1277–1286, 1991

    Article  Google Scholar 

  • Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? International Journal of Epidemiology 7: 347–358, 1978

    Article  PubMed  CAS  Google Scholar 

  • South Tees Health. EPO 90, South Cleveland Hospital, Middlesborough, 1990

    Google Scholar 

  • US Congress: Recombinant erythropoietin payment options for Medicare. Office of Technology Assessment, Washington Dc, 1990

  • Winearls CG, Pippard MJ, Downing MR, Reid C, et al. The effect of human EPO derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis, Lancet 2: 1175–1177, 1986

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, University of York, York, YO1 5DD, England

    Brenda Leese, John Hutton & Alan Maynard

Authors
  1. Brenda Leese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Hutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan Maynard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leese, B., Hutton, J. & Maynard, A. A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries. Pharmacoeconomics 1, 346–356 (1992). https://doi.org/10.2165/00019053-199201050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199201050-00006

Keywords

Search

Navigation